| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cutting Edge |
* Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology and Rheumatology Unit, and
Division of Pathology, H. San Raffaele Scientific Institute, and
Università Vita-Salute San Raffaele, Milan, Italy
Autoimmunity represents a caveat to the use of dendritic cells (DCs) as adjuvant for human vaccines. We derived DCs from normal BALB/c mice or from mice prone to autoimmunity (NZB x NZW) F1. We allowed DCs to phagocytose apoptotic thymocytes and vaccinated syngeneic animals. All mice developed anti-nuclear and anti-dsDNA Abs. Autoantibodies in normal mice were transient, without clinical or histological features of autoimmunity or tissue involvement. In contrast, autoimmunity was maintained in susceptible mice, which underwent renal failure and precociously died. The data suggest that DC vaccination consistently triggers autoimmune responses. However, clinical autoimmunity develops in susceptible subjects only.
This article has been cited by other articles:
|
|
 |
|
  D. A. Martin, K. Zhang, J. Kenkel, G. Hughes, E. Clark, A. Davidson, and K. B. Elkon Autoimmunity Stimulated by Adoptively Transferred Dendritic Cells Is Initiated by Both {alpha}beta and {gamma}{delta} T Cells but Does Not Require MyD88 Signaling J. Immunol., November 1, 2007; 179(9): 5819 - 5828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Wozniacka, A Lesiak, J Narbutt, J Kobos, S Pavel, and A Sysa-Jedrzejowska Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus Lupus, February 1, 2007; 16(2): 89 - 94. [Abstract] [PDF]
|
|
|
|
|
|
S. Wan, C. Xia, and L. Morel IL-6 Produced by Dendritic Cells from Lupus-Prone Mice Inhibits CD4+CD25+ T Cell Regulatory Functions J. Immunol., January 1, 2007; 178(1): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Baruah, I. E. Dumitriu, G. Peri, V. Russo, A. Mantovani, A. A. Manfredi, and P. Rovere-Querini The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells J. Leukoc. Biol., July 1, 2006; 80(1): 87 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Baruah, A. Propato, I. E. Dumitriu, P. Rovere-Querini, V. Russo, R. Fontana, D. Accapezzato, G. Peri, A. Mantovani, V. Barnaba, et al. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens Blood, January 1, 2006; 107(1): 151 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Hardin Dendritic cells: potential triggers of autoimmunity and targets for therapy Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv86 - iv90. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Chagnon, S. Tanguay, O. L. Ozdal, M. Guan, Z. Z. Ozen, J.-S. Ripeau, M. Chevrette, M. M. Elhilali, and L. A. Thompson-Snipes Potentiation of a Dendritic Cell Vaccine for Murine Renal Cell Carcinoma by CpG Oligonucleotides Clin. Cancer Res., February 1, 2005; 11(3): 1302 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schrama, R. Xiang, A. O. Eggert, M. H. Andersen, L. O. Pedersen, E. Kampgen, T. N. Schumacher, R. R. Reisfeld, and J. C. Becker Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2 J. Immunol., May 15, 2004; 172(10): 5843 - 5850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hardin Directing Autoimmunity to Nucleoprotein Particles: The Impact of Dendritic Cells and Interferon {alpha} in Lupus J. Exp. Med., March 17, 2003; 197(6): 681 - 685. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
